MaxCyte preliminary Q4 rev >$10M (+17% YoY); FY rev >$33.7M (+28%); adds 4 SPLs in 2021

MAXCYTE, INC.

2021-FY EPS reported -$0.21 revenue$33,894,100

Q4 2021 preliminary revenue >$10.0M (up from $8.5M in Q4 2020); core business revenue grew at least 37%.
Full year 2021 revenue >$33.7M (up from $26.2M in 2020); program-related revenue $2.5M (vs $3.3M in 2020).
Installed base grew to >500 instruments (from >400); 15 SPLs covering >95 programs, over 15% in clinic.
Precommercial milestone potential from SPLs exceeds $1.25B (up from >$950M in 2020).
New SPLs: Nkarta, Myeloid Therapeutics, Celularity, Sana Biotechnology; ExPERT VLx instrument launched.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.